Combination of PIM and JAK2 inhibitors synergistically suppresses MPN cell proliferation and overcomes drug resistance

Inhibitors of JAK2 kinase are emerging as an important treatment modality for myeloproliferative neoplasms (MPN). However, similar to other kinase inhibitors, resistance to JAK2 inhibitors may eventually emerge through a variety of mechanisms. Effective drug combination is one way to enhance therape...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Oncotarget 2014-05, Vol.5 (10), p.3362-3374
Hauptverfasser:	Huang, Shih-Min A, Wang, Anlai, Greco, Rita, Li, Zhifang, Barberis, Claude, Tabart, Michel, Patel, Vinod, Schio, Laurent, Hurley, Raelene, Chen, Bo, Cheng, Hong, Lengauer, Christoph, Pollard, Jack, Watters, James, Garcia-Echeverria, Carlos, Wiederschain, Dmitri, Adrian, Francisco, Zhang, JingXin
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Combined Chemotherapy Protocols - pharmacology Apoptosis - drug effects Cell Line, Tumor Cell Proliferation - drug effects Drug Resistance, Neoplasm - drug effects Humans Immunoblotting Janus Kinase 2 - antagonists & inhibitors Myeloproliferative Disorders - enzymology Protein Kinase Inhibitors - pharmacology Proto-Oncogene Proteins c-pim-1 - antagonists & inhibitors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!